With a very limited SBIR presence, Bone Biologics was founded to pursue regenerative medicine for bone - undertaking work with select strategic partners designed to build on the preclinical research of the Nell-1 protein. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. In October 2014, Bone Biologics Corporation - formerly Bone Biologics, Inc., completed its merger with AFH Acqusitions X Inc. The transaction took the form of a reverse merger of privately held Bone Biologics, Inc. and AFH Acquisition X, Inc, a fully-reporting company with the Securities and Exchange Commission. Upon completion of the merger, the combined company changed its name to Bone Biologics, Corp. Initially trading on OTC, firm now trades on NASDAQ:BBLG. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. Licensed from UCLA, the Company's platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. Lead product development and clinical studies are targeted on spinal fusion surgery. The Company's platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. Focused on bone regeneration in lumbar spinal fusion using NELL-1, which is a bone void filler, he Company is targeting spinal fusion as the first clinical indication of its platform technology and is in the development phase with this proposed medical device. The lead product, purified NELL-1, will be mixed with 510(k) cleared DBX Demineralized Bone Putty recommended for use in conjunction with a cleared intervertebral body fusion device. The NELL-1/DBX Fusion Device will consist of a single dose vial of NELL-1 recombinant protein freeze dried onto DBX. The NELL-1/DBX Fusion Device is intended for use in lumbar spinal fusion and may have a range of other applications, such as cervical spinal fusion. NELL-1 may also be used for application in other procedures, such as spine implants, non-union trauma cases, hip and knee revisions, implant coaching and osteoporosis.
